1
|
Sastre J, Vieitez JM, Gomez-España MA, Gil Calle S, Salud Salvia A, Suárez BG, Garcia-Alfonso P, Martinez de Castro E, Quintero Aldana GA, Reina-Zoilo JJ, González Flores E, Fernández MS, Guillen C, Garcia-Carbonero R, Safont MJ, La Casta Munoa A, García de Paredes B, Lopez R, Aranda E, Díaz-Rubio E. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.3507] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3507 Background: FOLFOXIRI+BEV has demonstrated a survival benefit compared with FOLFIRI plus BEV (TRIBE Lancet Oncol 2015) in first-line mCRC. Nevertheless, due to its safety profile, this schedule is not recommended for all pts. In addition, we have showed that the detection of ≥3 bCTCs is a poor prognostic factor for survival (MACRO The Oncologist 2012). The VISNU-1 trial compares FOLFOX + BEV vs FOLFOXIRI + BEV in pts with mCRC and ≥3 bCTCs. Progression-free survival (PFS) is the primary endpoint. Secondary endpoints included overall response rate (ORR) and overall survival (OS). Methods: This is an open, multicentric, randomized phase III trial. Patients with mCRC younger than 70 years, ECOG 0-1 were randomized to FOLFOX+BEV (arm A) or FOLFOXIRI+BEV (arm B), stratified per KRAS mutation (mutated vs WT) and number of involved organs (1 vs >1). Results: 349 pts were included in the ITT population; 177 in group A and 172 in group B. Characteristics of the pts, molecular profiling and safety analysis have been previously presented at ASCO 2018 and showed that this schedule had an acceptable toxicity profile. Efficacy analysis in the ITT population is shown in the table. Conclusions: In this population with very bad prognosis, our study met its primary endpoint. Pts who received FOLFOXIRI + Bev benefit for a statistically significative PFS and ORR. OS showed a trend of benefit in the experimental arm. According to these results, FOLFOXIRI-Bev could be considered an adequate treatment option for pts with mCRC and ≥3 bCTCs. Clinical trial information: 2012-000846-37. [Table: see text]
Collapse
Affiliation(s)
- Javier Sastre
- Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), Madrid/Spain, CIBERONC, Madrid, Spain
| | | | | | - Silvia Gil Calle
- H. Universitario y Regional y Virgen de la Victoria, Malaga, Spain
| | | | | | - Pilar Garcia-Alfonso
- Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | | | | | | | | | | | | | | | | | | | - Beatriz García de Paredes
- Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - Rafael Lopez
- University Clinical Hospital and Health Research Institute (IDIS), CIBERONC, Santiago de Compostela University School of Medicine, Santiago De Compostela, Spain
| | - Enrique Aranda
- IMIBIC, Reina Sofía Hospital, University of Córdoba, CIBERONC, Instituto de Salud Carlos III/ Spain, Córdoba, Spain
| | - Eduardo Díaz-Rubio
- Hospital Clínico San Carlos, Instituto de Investigación Hospital Clinico San Carlos (IdISSC), Madrid/Spain, CIBERONC, Madrid, Spain
| | | |
Collapse
|
2
|
Rodriguez CA, Guillen C, Garcia M, Sancho M, Gomez A, Ludena D, Cruz JJ. Abstract P4-08-07: Discordance between surrogated intrinsic subtypes defined by immunohistochemistry compared with PAM50 in ER positive / HER2 negative early breast cancer. Analysis of value of the status of the progesterone receptor and Ki67. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-08-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Classification by intrinsic subtypes by gene expression profiles of early-stage breast cancer (EBC) provides information of prognostic value and constitutes a tool to help in making therapeutic decisions. Several authors have proposed surrogated classifications based on immunohistochemistry results (IHC) in order to facilitate a classification with identical prognostic and predictive value. However, there is evidence that suggests a lack of correlation between these classifications.
The aim of this study was to evaluate the correlation between classification by intrinsic subtypes in patients with EBC ER+/ HER2neg, obtained by PAM50 and the surrogated classification proposed by St. Gallen 2013.
Methods: Samples from 12 centers from the spanish region of Castilla y León were analyzed by PAM50 (nCounterTM / Nanostring) at the University Hospital of Salamanca. The results obtained were compared with the surrogate classification of St.Gallen'13 from local reports. Tumors of patients pre and post-menopausal tests T1-2, N0-N1mi, grade I-II that met criteria for inclusion of the regional evaluation program through ProsignaTM were included.
Results: Between August'15 and December'17, 264 samples were analyzed. All patients were classified by IHC as lum-A or lum-B. In total 113 cases were reclassified by PAM50 (43%). The change of LumA by IHC to Lum-B by PAM50 was 18%, while Lum-B by IHC to Lum-A by PAM50 was 58% (n = 89). In those cases considered Lum-B by IHC based only in a value of Ki67>14% (n = 93), 54% was reclassified to Lum-A. Conversely, when low expression (negative or <20%) of Progesterone Receptor (PR) was used as the single criterion of Lum-B by IHC (n = 44), PAM50 reclassified 33 cases as Lum-A (75%). Applying the Kappa test to analyze the concordance between the 2 tests, a coefficient of 0.203 (low agreement) was obtained, statistically significant (0.000).
Conclusion: The surrogated classification by IHC of intrinsic subtypes in EBC ER+/HER2neg shows a low concordance with PAM50 analysis, and cannot be considered adequate. In particular, the presence of negative or <20% PR as the only criterion seems the least appropriate and should not be recommended for a surrogated classification of a tumor as Lum-B, overestimating the real risk of numerous patients. PAM50 allowed the reclassification in more than 40% of cases, especially csaes considered Lum-B by IHC.
Citation Format: Rodriguez CA, Guillen C, Garcia M, Sancho M, Gomez A, Ludena D, Cruz JJ. Discordance between surrogated intrinsic subtypes defined by immunohistochemistry compared with PAM50 in ER positive / HER2 negative early breast cancer. Analysis of value of the status of the progesterone receptor and Ki67 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-07.
Collapse
Affiliation(s)
- CA Rodriguez
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - C Guillen
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - M Garcia
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - M Sancho
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - A Gomez
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - D Ludena
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| | - JJ Cruz
- Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain
| |
Collapse
|
3
|
Moure Z, Sulleiro E, Iniesta L, Guillen C, Molina I, Alcover MM, Riera C, Pumarola T, Fisa R. The challenge of discordant serology in Chagas disease: The role of two confirmatory techniques in inconclusive cases. Acta Trop 2018; 185:144-148. [PMID: 29775566 DOI: 10.1016/j.actatropica.2018.05.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Revised: 05/10/2018] [Accepted: 05/13/2018] [Indexed: 10/16/2022]
Abstract
Serodiscordance in Chagas disease (CD) remains a challenge since individuals with inconclusive results are clinically complicated to manage. This work, conducted outside the endemic area, aims to compare two different confirmatory techniques for the diagnosis of CD in individuals without a definitive diagnosis, to analyze the performance of the screening techniques in this group of patients, and to describe the serological follow-up of these subjects over time. Sera from 48 individuals with repeatedly discordant results by one recombinant enzyme immunoassay (r-ELISA) and one native ELISA (n-ELISA), were included in the study. Confirmatory procedures were performed through TESA-blot, using trypomastigote antigens of Trypanosoma cruzi, and in-house WB (IH-WB) using a lysate from T. cruzi epimastigotes. Of the 48 sera, TESA-blot confirmed 22 (45.8%) cases and IH-WB 17 (35.4%). Both techniques showed a substantial agreement (k = 0.604). Confirmation defined as the positivity of one of the ELISA and at least one of the confirmatory tests was reached in 24/48 (50%) cases. We found a great dispersion of r-ELISA index values, especially among individuals with confirmatory negative results, ranging from 0.03-6.2. Additionally, n-ELISA yielded a better performance than r-ELISA in this cohort of patients, showing a significantly greater agreement with the confirmatory methods. Our results indicate that either confirmatory test could be an efficient tool to solve inconclusive cases regardless of which form of the parasite's life cycle they use. Also, most individuals remain with discordant serology throughout the short-term follow-up period time of study. Finally, we consider that it is necessary to establish a reference test feasible and commercialized in all areas to solve the problem of inconclusive results.
Collapse
|
4
|
Barquín García AM, Martinez Saez O, Serrano Domingo JJ, Martín Huertas R, Villamayor Delgado M, Saavedra Serrano C, Corral de la Fuente E, Reguera Puertas P, LONGO FEDERICO, Pachón Olmos V, Rodríguez Garrote M, Guillen C, Carrato A, Ferreiro REYES. Prognostic relevance of primary tumor location in stage III and II colon cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
703 Background: Primary tumor location of colon cancer (CC) is emerging as an important prognostic factor owing to distinct biological features. However, this factor still does not represent a prognostic parameter when deciding for adyuvant or palliative chemotherapy. In a meta-analysis of 66 studies including patients with all stages of disease, left-sided primary tumor location was associated with a significantly reduced risk of death and this was independent of other prognostic factors. Methods: We retrospectively included patients with stage II and III CC that underwent surgical resection between 2009 and 2014 HURyC. We performed a multivariate Cox model analysis to estimate if tumor location is an independent prognostic factor for overall survival (OS). The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes ( < 12 or ≥ 12), perforation, grade, use of adyuvant chemotherapy and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (267 left sided and 297 right sided). The median follow-up of the entire cohort was 49 months. Globally, right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.74, p: 0.128; HR: 0.94, p: 0.75, respectively). By stages, stage II right sided CC seemed to show better DFS (HR: 0.45, p: 0.02), although no significant differences were found in OS (HR: 1.004, p: 0.98). Stage III right sided CC was not significantly associated with better DFS or OS in comparison with left sided CC (HR: 0.87, p: 0.585; HR: 0.66, p: 0.19, respectively). Conclusions: The multivariate analysis did not show significant differences in terms of prognostic relevance of primary tumor location in the adyuvant setting.
Collapse
|
5
|
Martinez Saez O, Barquín García AM, Saavedra Serrano C, Corral de la Fuente E, Serrano Domingo JJ, Martín Huertas R, Villamayor Delgado M, LONGO FEDERICO, Reguera Puertas P, Pachon V, Rodríguez Garrote M, Guillen C, Carrato A, Ferreiro Monteagudo R. Benefit of adjuvant treatment in stages II and III colon cancer: Experience at the Ramón y Cajal University Hospital. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
842 Background: The standard adjuvant treatment for patients with stage III colon cancer is 6 months with fluoropyrimidines and oxaliplatin. The Intergroup Trial INT-0035 was the first large-scale study to demonstrate a significant reduction in the risk of death with adjuvant FU plus levamisole in patients with stage III colon cancer. In the MOSAIC study, the addition of oxaliplatin to fluoropyrimidines in patients with resected stage II to III colon cancer showed OS and DFS benefit of oxaliplatin. However, no significant benefit was observed in either DFS or OS in patients with stage II disease, therefore the benefit of adjuvant chemotherapy is still controversial in those patients. Methods: We retrospectively included patients with stages II and III colon cancer that were operated between 2009 and 2014 in the University Ramón y Cajal Hospital from Madrid. We calculate DFS and OS at 48 months and we perform a multivariable Cox model analysis to estimate the benefit of the chemotherapy in each stage. The model was further adjusted by including the following confounders: ECOG-PS, number or removed nodes ( < 12 or ≥ 12), grade and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (281 stage II and 283 stage III). 259 received chemotherapy and 305 did not. The median follow-up in the entire cohort was 49 months. The median DFS and OS were not reached at the moment of the analysis. DFS and OS at 48 months were both 78.5%. Globally, chemotherapy did not improve DFS (HR 1.05, p: 0.83) but OS was significantly better (HR 0.47, p: 0.001). By stage, chemotherapy did not improve DFS in stage II (HR: 1.6, p: 0.2) nor OS (HR 0.76, p: 0.43). In stage III, chemotherapy showed a trend to improve DSF (HR: 0.61, p: 0.075) and did improve OS (HR: 0.31, p < 0.0001). Conclusions: The multivariable analysis showed a chemotherapy benefit in patients with stage III colon cancer, with a 39% reduction in the risk of recurrence and a 69% in the risk of death; however, in stage II patients these benefits were not found either in DFS or OS.
Collapse
|
6
|
Martinez Saez O, Barquín García AM, Villamayor Delgado M, Saavedra Serrano C, Corral de la Fuente E, Serrano Domingo JJ, Martín Huertas R, Reguera Puertas P, LONGO FEDERICO, Pachon V, Rodríguez Garrote M, Guillen C, Carrato A, Ferreiro Monteagudo R. Impact of adding oxaliplatin to fluoropyrimidines in the adjuvant colon cancer: Experience in Ramon y Cajal University Hospital. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
815 Background: The addition of oxaliplatin to fluorouracil and leucovorin as adjuvant therapy for patients with stage II and III colon cancer (CC) has been analyzed in two large, randomized trials, MOSAIC and C-07 trials. The updated results of these studies showed that the addition of oxaliplatin enhances overall survival by approximately 5% in patients with stage III disease but has no effect in patients with stage II disease. Methods: We retrospectively included patients with stage II and III CC that were operated between 2009 and 2014 in the Ramón y Cajal University Hospital from Madrid. We perform a multivariable Cox model analysis to estimate the benefit of the chemotherapy stratifying by oxaliplatin in each stage. The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes, perforation, obstruction, grade and age. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (281 stage II and 283 stage III). 305 did not receive any chemotherapy, 61 received monotherapy with fluoropyrimidines (FP) and 198, FP and oxaliplatin. The median follow-up in the entire cohort was 49 months. Globally, adjuvant chemotherapy (either with FP alone or with the combination with oxaliplatin) showed no benefit in DFS (HR of 1.18 and 0.98, respectively). The benefit in OS was significant either for FP alone (HR: 0.46, p: 0.029) and for the combination treatment (HR: 0.41, p: 0.001). Patients with stage II treated with FP in monotherapy showed no benefit, neither in DFS nor OS (HR for DFS: 2.2, p: 0.1; HR for OS: 0.5, p: 0.22). The benefit was neither seen with the addition of oxaliplatin (HR for DFS: 2, p: 0.11; HR for OS: 0.85, p: 0.7). Stage III patients treated with FP presented a HR for DFS of 0.76 (p: 0.5) and a HR for OS of 0.42 (p: 0.087). The HR for DFS with oxaliplatin was 0.53 (p: 0.07). A significant improvement in OS was observed, with a HR of 0.22 (p < 0.001). Conclusions: The addition of oxaliplatin in the adjuvant treatment of stage III patients showed a trend towards improvement in DFS and a significant benefit in OS compared to not receiving chemotherapy. On the contrary, patients with stage II did not benefit from this treatment, neither in DFS nor OS.
Collapse
|
7
|
Barquín García AM, Martinez Saez O, Corral de la Fuente E, Serrano Domingo JJ, Martín Huertas R, Villamayor Delgado M, Saavedra Serrano C, Rodríguez Garrote M, Pachón Olmos V, Reguera Puertas P, LONGO FEDERICO, Guillen C, Carrato A, Ferreiro REYES. Impact of adyuvant chemotherapy treatment according to tumor primary location in colorectal cancer: Experience at University Hospital Ramon y Cajal (HURyC) Madrid. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.4_suppl.655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
655 Background: Adyuvant chemotherapy is a unified therapeutic principle in colon cancer (CC). However, many prognostic factors are arising to determine who really benefits from adyuvant chemotherapy in order to avoid overtreatment. Primary tumor location of CC is emerging as an important prognostic factor owing to distinct biological features. However, there is hardly any evidence showing the benefit of treatment according to primary tumor location. Methods: We retrospectively included patients with stage II and III CC that underwent surgical resection between 2009 and 2014 HURyC. We performed a multivariable Cox model analysis to estimate the benefit of chemotherapy according to tumor location in terms of DFS and OS. The model was further adjusted by including the following confounders: ECOG-PS, number of removed nodes ( < 12 or ≥ 12), use of adyuvant chemotherapy and age. A covariate was considered a confounder factor if the difference between the adjusted and unadjusted coefficient of chemotherapy varied > 10%. Stata 13.1 was used to analyze the data. Results: 564 patients were identified (267 left sided and 297 right sided). The median follow-up of the entire cohort was 49 months. Globally, chemotherapy did not improve DFS neither in right sided or left sided CC (HR: 0.81, p: 0.58; HR 1.31, p: 0.4, respectively). As for OS, it was improved when adding chemotherapy in both sides (right sided CC HR 0.51, p: 0.061 and left sided CC HR 0.42, p: 0.009). By stages, chemotherapy did not improve DFS or OS according to tumor localization in stage II. In right sided stage III, there was a trend to improve both DFS and OS (HR: 0.54, p: 0.14; HR: 0.39, p: 0.1, respectively). In left sided stage III, there was a trend to improve DFS (HR: 0.66, p: 0.36) and there was an improvement in OS (HR: 0.23, p < 0.001). Conclusions: The multivariable analysis showed benefit of chemotherapy in both right and left sided CC in terms of OS, exhibiting more benefit those patients with left sided CC.
Collapse
|
8
|
Benavides M, Guillen C, Rivera F, Gallego J, Lopez-Martin J, Küng M. Abstract CT130: PANOVA: A phase II study of TTFields (150kHz) concomitant with standard chemotherapy for front line therapy of advanced pancreatic adenocarcinoma. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-ct130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Ductal adenocarcinoma of the pancreas is the fourth leading cause of cancer mortality in the US. The disease is mostly unresectable at the time of diagnosis, making chemotherapy the backbone of therapy. TTFields are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of recurrent and newly diagnosed glioblastoma by the FDA. TTFields act by delivering intermediate frequency alternating electric fields to the tumor, and act predominantly by disrupting the formation of the mitotic spindle during metaphase and by dielectrophoretic dislocation of intracellular constituents during cytokinesis. In vitro, TTFields led to reduction in the proliferative potential of pancreatic cancer cell lines with or without chemotherapies, and to a subsequent reduction in their clonogenic potential. In vivo, TTFields led to a significant reduction in tumor volumes. PANOVA was the first trial testing TTFields (150kHz) in pancreatic cancer patients. Results from the first arm of the study, testing TTFields in combination with gemcitabine, have demonstrated superiority in efficacy compared to historical controls, with median PFS of 8.3 months and median OS of 14.9 months (Rivera F. et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 269)).
Methods
Twenty advanced pancreatic cancer patients were enrolled in the second arm of PANOVA and treated with TTFields in combination with gemcitabine concomitant to nab-paclitaxel. All patients had unresectable tumors, an ECOG performance score of 0-1 and no prior therapy. The primary endpoint was the incidence and severity of treatment emergent adverse events.
Results
The median age was 68.2 (range – 58-81) and most patients (65%) had an ECOG score of 1. Twelve patients (60%) had distant metastases. The Median number of gem/nab-paclitaxel cycles was 5.0, and median number of TTFields cycles was 7.5. Ten patients (50%) had serious AEs during the study period. Eleven patients (55%) had treatment-related skin toxicity, of which 5 had grade 3 toxicity. No TTFields-related serious AEs were reported. The median PFS was 12.7 months (95% CI 5.4, NA). PFS rate at 6 months was 65%. Of the evaluable tumors, 40% had partial response and another 47% stable disease. The median OS was not reached, and the 1-year survival rate was 72%.
Conclusions
TTFields concomitant to gemcitabine and nab-paclitaxel are tolerable and safe for advanced pancreatic cancer patients, with promising clinical outcome which doubled published historical data. A phase III trial is planned, testing the efficacy of TTFields combined with gemcitabine and nab-paclitaxel in locally-advanced pancreatic cancer patients.
Citation Format: Manuel Benavides, Carmen Guillen, Fernando Rivera, Javier Gallego, Jose Lopez-Martin, Marc Küng. PANOVA: A phase II study of TTFields (150kHz) concomitant with standard chemotherapy for front line therapy of advanced pancreatic adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr CT130. doi:10.1158/1538-7445.AM2017-CT130
Collapse
Affiliation(s)
- Manuel Benavides
- 1Hospital Universitario Regional y Virgen de la Victoria, Andalucía, Spain
| | | | | | | | | | - Marc Küng
- 6Hôpital Fribourgeois, Fribourg, Switzerland
| |
Collapse
|
9
|
Benavides M, Guillen C, Rivera F, Gallego J, Lopez-Martin JA, Küng M. PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma—Updated efficacy results. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.e15790] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15790 Background: TTFields are a non-invasive, regional antimitotic treatment modality, which has been approved for the treatment of glioblastoma by the FDA. TTFields predominantly act by disrupting the formation of the mitotic spindle during metaphase. TTFields were effective in multiple preclinical models of pancreatic cancer. PANOVA was the first trial testing TTFields in pancreatic cancer patients. Results from the first arm of the study, testing TTFields in combination with gemcitabine, have demonstrated superiority in efficacy compared to historical controls (Rivera F. et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 269). Methods: Twenty advanced pancreatic cancer patients were enrolled in the second arm of PANOVA and treated with TTFields in combination with gemcitabine concomitant to nab-paclitaxel. All patients had unresectable tumors, an ECOG performance score of 0-1 and no prior therapy. The primary endpoint was the incidence and severity of adverse events. Results: The median age was 68.2 (range – 58-81) and most patients (65%) had an ECOG score of 1. Twelve patients (60%) had distant metastases. Ten patients (50%) had serious AEs during the study period. Eleven patients (55%) had treatment-related skin toxicity, of which 5 had grade 3 toxicity. No TTFields-related serious AEs were reported. The median PFS was 12.7 months (95% CI 5.4, NA): 9.3 months in patients with metastatic disease, and not reached in locally-advanced patients. PFS rate at 6 months was 65%: 50% in metastatic disease and 87.5% in locally advanced patients. Of the evaluable tumors, 40% had partial response and another 47% stable disease. The median OS was not reached, and the 1-year survival rate was 72% (62.5% in metastatic disease and 87.5% in locally advanced disease). Conclusions: TTFields concomitant to gemcitabine and nab-paclitaxel are safe for advanced pancreatic cancer patients, with promising clinical outcome which doubled historical data. A phase III trial is planned, testing the efficacy of TTFields combined with gemcitabine and nab-paclitaxel in locally-advanced pancreatic cancer patients. Clinical trial information: NCT01971281.
Collapse
Affiliation(s)
| | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | - Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Gallego
- Servicio de Oncología Médica, Hospital General Universitario de Elche, Elche, Spain
| | | | - Marc Küng
- Kantonsspital, Fribourg, Switzerland
| |
Collapse
|
10
|
Pachón Olmos V, Reguera Puertas P, Ferreiro Monteagudo R, LONGO FEDERICO, Rodríguez Garrote M, Vaz Salgado MÁ, Guillen C, Gion Cortés M, Molina CerrilloMD J, Martinez Saez O, Villamayor Delgado M, Die Trill J, Tobaruela de Blas E, Moreno Montes I, García Pérez JC, Pina JD, Caminoa-Lizarralde Aiza MA, Sempere Ortega C, López-Campos F, Carrato A. Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
790 Background: The role of adjuvant chemotherapy (AC) after chemoradiotherapy and surgery in stage II and III of rectal cancer is not well defined. Neither the regimen nor the duration is clear. Besides, guidelines from different expert groups are conflicting. Methods: 224 patients diagnosed from January 2003 to December 2013 with rectal adenocarcinoma T3/T4 and/or positive node staged by ultrasound or magnetic resonance imaging was collected retrospectively from the Pathology Department data base. Results: Of the 224 patients 61.6% were male, median of age at diagnosis 68.6 years (range 31.3-85.4). All of them received 50.4 Gy with different concomitant regimens (capecitabine, continuous infusion of fluoracil or bolus of fluoracil-leucovorin). 13.4% of patients achieved a pathological complete response. 76.8% of the cohort received adjuvant chemotherapy. The main reasons for not receiving chemotherapy were ECOG ≥ 2, surgery complications and a decision of the patient. 51.2% of patients received an oxaliplatin based regimen and the median time of chemotherapy duration was 4 months (range 1-6 months). Local relapse was diagnosed in 6.3% of patients while a systemic relapse was found in 22.3%. Patients without AC had a mean overall survival (OS) of 85.5 months (CI 95% 70.7-100.4) versus 119.8 monts (CI 95% 110.8-128.8) in the AC cohort (p 0.002) without reaching the median after 58 months (range 8-153.9) median follow-up. Disease free survival (DFS) was also better in the AC cohort with a mean DFS of 104 months (CI 95% 94.3-113.6) versus 71.4 months (CI 95% 55.4-87.4), p = 0.01. Conclusions: AC after chemoradiotherapy and surgery in stage II and III rectal cancer as a standard does not exist. In our cohort, AC showed a significant improve in OS and DFS, but the limitations of a retrospective study should be considered, as well as the impact of surgery on metastasis and salvage chemotherapies. Randomized studies are clearly needed.
Collapse
Affiliation(s)
| | | | | | - FEDERICO LONGO
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | | | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | - Maria Gion Cortés
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Olga Martinez Saez
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Javier Die Trill
- General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Irene Moreno Montes
- General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Juan Diego Pina
- General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | | | | | - Alfredo Carrato
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| |
Collapse
|
11
|
Rivera F, Polo Marques E, Aranda E, Fernandez-Martos C, La Casta Munoa A, Guillen C, Lopez R, Gil S, Lema L, Aparicio J, Martinez Villacampa M, Pisa A, Borrega P, Lopez-Vivanco G, Garcia Alfonso P. Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.4_suppl.751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
751 Background: In the VELOUR trial, adding Z to FOLFIRI improves OS, PFS and RR in mCRC pts progressing after oxaliplatin ±biologic agents. The ASQoP trial (NCT01571284) was designed to gather safety and QoL data from mCRC in real-life setting. We report data collected by the Spanish investigators. Methods: ASQoP is single-arm, open-label trial evaluating safety and QoL of Z in mCRC pts as 2nd line. Eligible pts received Z (4mg/kg) q2wks on day 1/cycle, followed by FOLFIRI (dosing was at physician’s discretion) until disease progression, unacceptable toxicity, death, or investigator/pt decision. The EQ-5D was used for utility index (UI) measure and the EORTC QLQ-C30 as generic cancer instrument. QoL population consisted of pts completing the questionnaire at baseline and ≥1 assessment post-baseline and received ≥1 part of 1 dose of study treatment. Results: The safety population comprised 77 pts with ≥1 completed cycle of treatment. Grade (G)3/4 AEs were reported in 72.7% of pts (vs 83.5% in VELOUR), being G3 most commonly reported. There was no G4 hypertension, stomatitis, or proteinuria. G4 Diarrhea was found in 1.3% of pts. Mean baseline UI was 0.7 (95% CI, 0.63-0.78) in 51 pts, and remained relatively stable at cycles 3 (n=39) and 7 (n=24), with a mean (±SD) change from baseline of 0.03 (±0.26) and -0.06 (±0.35), respectively. Mean baseline global health status score was 63.1 (95% CI, 55.8-70.4) in 54 pts, and remained stable up to cycle 9 with a mean (±SD) change from baseline of 4.17 (±38). Conclusions: Thisanalysis has identified no new safety signals and suggests an acceptable toxicity profile with a relatively stable UI and QoL in Spanish mCRC pts in the real-life setting. [Table: see text]
Collapse
Affiliation(s)
- Fernando Rivera
- Hospital Universitario Marques de Valdecilla, Santander, Spain
| | | | | | | | | | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | - Rafael Lopez
- Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain
| | - Silvia Gil
- H. Universitario Carlos Haya, Malaga, Spain
| | - Laura Lema
- Hospital 12 de Octubre Avda de Cordoba, Madrid, Spain
| | - Jorge Aparicio
- Hospital Universitario y Politecnico de La Fe, Valencia, Spain
| | | | - Aleydis Pisa
- Institut Oncologic del Valles, Corporacio Sanitària Parc Tauli, Consorci Sanitari de Terrassa, Sabadell, Spain
| | | | | | | |
Collapse
|
12
|
Guillen C, Salazar-Lopez MT, Rubio MD, Chiva M, Perez-Rodrigo S, Solera J, Martinez P, Pachón Olmos V, Ferreiro Monteagudo R, Earl J, Cortez Castedo SP, Villamayor-Delgado M, Hernandez Sarmiento S, Humanes MI. Compliance and impact of screening on individuals at high risk of breast and ovarian cancer syndrome (BOCS). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e13054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain
| | | | | | - Miguel Chiva
- Radiology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Jesus Solera
- Instituto Genetica Molecular, Hospital La Paz, Madrid, Spain
| | - Pilar Martinez
- Laboratorio de Genética Molecular. La Paz University Hospital, Madrid, Spain
| | | | | | - Julie Earl
- Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
| | | | | | - Samuel Hernandez Sarmiento
- Medical Oncology Unit; Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
| | | |
Collapse
|
13
|
Reguera Puertas P, Pachón Olmos V, Ferreiro Monteagudo R, Longo F, Guillen C, Rodríguez Garrote M, Vaz Salgado MÁ, Gion Cortés M, Madariaga Urrutia A, Cortés Salgado A, Cortez Castedo SP, Muñoz del Toro J, Saavedra Serrano C, Hervás Morón A, Sempere Ortega C, Die Trill J, García Pérez JC, Pina JD, Caminoa-Lizarralde Aiza MA, Carrato A. Outcomes of elderly patients receiving neoadjuvant chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer in a retrospective cohort. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e15145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Federico Longo
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | | | - Maria Gion Cortés
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | | | | | | | | | | | | | - Javier Die Trill
- General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Juan Diego Pina
- General Surgery Department, Ramon y Cajal University Hospital, Madrid, Spain
| | | | - Alfredo Carrato
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
| |
Collapse
|
14
|
Guillen C, Fernandez-Felix BM, Sanchez MM, Santiago Crespo JA, Olaverri A, Soriano-Rodrà Âguez MC, Molina-Garrido MJ. Decision-making in the older patient with diagnosis of cancer: Sarcopenia and frailty as predictors of toxicity to chemotherapy—ONCOSARCO project. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e21525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain
| | | | | | - JA Santiago Crespo
- Medical Oncology Department, Hospital Virgen de la Luz in Cuenca, Cuenca, Spain
| | | | | | - MJ Molina-Garrido
- Medical Oncology Department, Hospital Virgen de la Luz in Cuenca, Cuenca, Spain
| |
Collapse
|
15
|
Van Cutsem E, Lenz HJ, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno M, Csõszi T, Wasan H, Melichar B, Karasek P, Macarulla TM, Guillen C, Kalinka-Warzocha E, Horvath Z, Prenen H, Schlichting M, Ibrahim A, Bendell JC. MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.4007] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Junji Furuse
- Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan
| | - Josep Tabernero
- Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Barcelona, Spain
| | - Volker Heinemann
- Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Munich, Germany
| | - Tatsuya Ioka
- Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
| | - Igor Bazin
- N. N. Blokhin Russian Cancer Research Center, Moscow, Russia
| | - Makoto Ueno
- Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
| | - Tibor Csõszi
- Jász-Nagykun Szolnok Megyei Hetényi Géza Kórház-Rendelointézet, Szolnok, Hungary
| | - Harpreet Wasan
- Hammersmith Hospital, Imperial College, London, United Kingdom
| | - Bohuslav Melichar
- Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic
| | - Petr Karasek
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
| | | | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain
| | | | | | - Hans Prenen
- Digestive Oncology Unit, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium
| | | | | | | |
Collapse
|
16
|
Rivera F, Gallego J, Guillen C, Benavides M, Lopez-Martin JA, Kueng M. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.4125] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Gallego
- Servicio de Oncología Médica, Hospital General Universitario de Elche, Elche, Spain
| | - Carmen Guillen
- Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain
| | | | | | - Marc Kueng
- Cantonal Hospital Fribourg, Fribourg, Switzerland
| |
Collapse
|
17
|
Jimenez-Marco T, Fisa R, Girona-Llobera E, Cancino-Faure B, Tomás-Pérez M, Berenguer D, Guillen C, Pujol A, Iniesta L, Serra T, Mascaró M, Gascó J, Riera C. Transfusion-transmitted leishmaniasis: a practical review. Transfusion 2016; 56 Suppl 1:S45-51. [DOI: 10.1111/trf.13344] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 07/15/2015] [Accepted: 08/10/2015] [Indexed: 11/28/2022]
Affiliation(s)
- Teresa Jimenez-Marco
- Fundació Banc de Sang i Teixits de les Illes Balears
- Institut Universitari d'Investigació en Ciències de la Salut (IUNICS); Majorca, Spain
| | - Roser Fisa
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Enrique Girona-Llobera
- Fundació Banc de Sang i Teixits de les Illes Balears
- Institut Universitari d'Investigació en Ciències de la Salut (IUNICS); Majorca, Spain
| | - Beatriz Cancino-Faure
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Miriam Tomás-Pérez
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Diana Berenguer
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Carmen Guillen
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Alba Pujol
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Laura Iniesta
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| | - Teresa Serra
- Institut Universitari d'Investigació en Ciències de la Salut (IUNICS); Majorca, Spain
| | | | - Joan Gascó
- Son Espases University Hospital; Majorca Spain
| | - Cristina Riera
- Laboratori de Parasitologia, Facultat de Farmàcia; Universitat de Barcelona; Barcelona Spain
| |
Collapse
|
18
|
Rivera F, Gallego J, Guillen C, Benavides M, Lopez-Martin JA, Betticher DC, Kueng M. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.4_suppl.269] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
269 Background: TTFields are alternating electric fields delivered to the region of the tumor by means of non-invasive transducer arrays. TTFields interfere with mitotic spindle formation, thus having an anti-mitotic activity. In pancreatic cancer, TTFields decreased proliferation and clonogenic potential in vitro, and reduced tumor volume in vivo. The PANOVA trial was designed to test TTFields, combined with chemotherapy, in pancreatic cancer. Methods: Twenty patients with advanced pancreatic adenocarcinoma were enrolled in a prospective, single arm study of TTFields at 150 kHz, concomitant with standard weekly gemcitabine. All patients had histologically-confirmed unresectable tumors, with an ECOG performance score of 0-1 and no prior chemotherapy or radiation therapy. The primary endpoint was incidence and severity of treatment emergent adverse events (AEs). Secondary endpoints included progression free survival (PFS), PFS rate at 6 months, overall survival (OS) and response rate. Results: The median age was 73 (range – 49-81) and 60% of the patients were females. Most patients (80%) had an ECOG score of 1. Twelve patients (60%) had distant metastases, while the others had locally advanced disease. Median compliance with TTFields was 78% (14 hours/day), with median duration of 5 months. Fourteen patients (70%) had serious (grade 3-5) AEs during the study period. Six patients (30%) had hematological, 45% gastrointestinal and 15% pulmonary AEs. Ten patients (50%) had treatment-related skin toxicity, of which only 2 were grade 3, both resolved with appropriate treatment. No TTFields-related serious AEs were reported. The median PFS was 8.3 months (95% CI 4.3, 10.3). PFS rate at 6 months was 56%. Of the evaluable tumors, 30% had partial response and another 30% stable disease. The median OS was 14.9 months and 1-year survival rate was 55%. Conclusions: TTFields concomitant to gemcitabine are tolerable and safe for advanced pancreatic cancer patients. The efficacy results are promising and support further research in this indication. An extension of the PANOVA protocol, including 20 additional patients who receive gemcitabine, nab-paclitaxel and TTFields is ongoing. Clinical trial information: NCT01971281.
Collapse
Affiliation(s)
- Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Javier Gallego
- Servicio de Oncología Médica, Hospital General Universitario de Elche, Elche, Spain
| | | | | | | | | | - Marc Kueng
- Cantonal Hospital Fribourg, Fribourg, Switzerland
| |
Collapse
|
19
|
Earl J, Garcia-Nieto S, Martinez-Avila J, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendia E, Lobo E, Malats N, Carrato A, Guillen C. 428 KRAS mutant circulating free DNA (cfDNA) and circulating tumor cell (CTC) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)30262-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Pellacani G, Peris K, Guillen C, Clonier F, Larsson T, Venkata R, Puig S. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. J Eur Acad Dermatol Venereol 2015; 29:2192-8. [PMID: 26300464 PMCID: PMC5049592 DOI: 10.1111/jdv.13211] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Accepted: 05/22/2015] [Indexed: 11/30/2022]
Abstract
Background Actinic keratoses (AKs) are precursors to invasive squamous cell carcinoma and can progress if untreated. Limited data support the use of ingenol mebutate to treat AKs on more than one area of the body simultaneously. Objective To investigate safety, efficacy and treatment satisfaction when treating separate areas simultaneously or sequentially with different concentrations of ingenol mebutate gel. Methods In this phase IIIb study (NCT01787383), patients with clinically visible, non‐hyperkeratotic AKs on two separate treatment areas (face/scalp and trunk/extremities) were randomized to simultaneous or sequential treatment with ingenol mebutate gel (0.015% and 0.05%). Endpoints included composite local skin response (LSR) score 3 days after first application, complete AK clearance and percentage reduction in AKs at week 8. Results There were no statistically significant differences between simultaneous (n = 101) and sequential (n = 98) groups in composite LSR score (10.4 vs. 9.7), complete clearance (52.7% vs. 46.9%) or percentage reduction in AKs (83.4% vs. 79.1%). Mean composite LSR scores on face/scalp and trunk/extremities were similar for both groups. Adverse event (AE) incidence was comparable between groups, the most common treatment‐related AEs being pruritus and pain at the application site. Conclusion Treating AKs with ingenol mebutate simultaneously or sequentially gave similar results in terms of tolerability (LSR score, AEs) and efficacy (complete clearance). Therefore, the physician and patient can select the most convenient treatment regimen, with confidence in achieving a similar outcome.
Collapse
Affiliation(s)
- G Pellacani
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy
| | - K Peris
- Department of Dermatology, Catholic University of Rome, Rome, Italy
| | - C Guillen
- Department of Dermatology, Instituto Valenciano de Oncología, Valencia, Spain
| | | | | | | | - S Puig
- Melanoma Unit, Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona & CIBERER, Instituto de Slud Carlos III, Barcelona, Spain
| |
Collapse
|
21
|
LONGO FEDERICO, Pachon V, Guillen C, Ferreiro R, Rodriguez Garrote M, Puertas PR, Madariaga A, Gion M, Lopez Hervas P, Galindo J, Gonzalez Lizarbe E, Varona C, Montans J, Earl J, Grande E, Olmedo Garcia ME, Garrido P, Lobo E, Palacios J, Carrato A. Prognostic factors in advanced gastric cancer after second-line treatment. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
201 Background: Advanced gastric cancer (AGC) is a highly lethal disease worldwide with a median overall survival (OS) of less than 12 months. Ramucirumab was the first targeted agent to show survival benefit in the second-line (2L) treatment of AGD. From the REGARD trial, women exhibited a trend towards a worse survival when compared to men. Methods: We retrospectively analyzed the outcome of a Spanish cohort of 55 AGC patients who had received at least two consecutive chemotherapy lines of treatment at our institution. We preselected some clinical parameters (age, gender, Lauren subtype, Her-2 status, grade of differentiation, primary tumor localization and resection, TNM stage, neoadjuvant/adjuvant administration, mono/polychemotherapy in 2L, irinotecan- or taxane-based 2L, Trastuzumab treatment, and administration of third-lines [3L]) to be tested as potential prognostic factors. We focused our analysis on the gender effect in OS after 2L treatment in AGC. The SPSS software package was used for all statistical analyses (Mann-Whitney U test, Chi Square, Kaplan-Meier, Cox regression). Results: Women, diffuse subtype, poorly differentiated tumors, sub-cardia location, single-agent 2L and 3L administration were the clinical characteristics with a significant shorter OS by the univariable analysis. Median OS of women (5 months, 95%CI 3.9-6.0) was significant lower than that in men (13 months, 95%CI 7.9-18.0) by both Log-Rank and Breslow tests (p 0.002). We found no significant differences in age, progression-free survival or time-on-treatment between men and women. Female gender was significantly associated with more taxane-based 2L and with less 3L treatment administration. When 3L treatment administration was excluded in the multivariable analysis, female gender was the only independent prognostic factor of all the clinical parameters included in our review (HR 0.33, 95%CI 0.15-0.75, p 0.008). Conclusions: Our retrospective study found that gender, Lauren subtype, grade of differentiation, primary tumor location, polychemotherapy and 3L administration may be potential prognostic factors in AGC after 2L treatment. Female gender was an independent prognostic factor in our Spanish cohort.
Collapse
Affiliation(s)
- FEDERICO LONGO
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Vanessa Pachon
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Reyes Ferreiro
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | | | | | - Ainhoa Madariaga
- Hospital Universitario Ramón y Cajal, Medical Oncology Department., Madrid, Spain
| | - Maria Gion
- Hospital Universitario Ramón y Cajal, Medical Oncology Department., Madrid, Spain
| | - Pedro Lopez Hervas
- Hospital Universitario Ramón y Cajal, General Surgery Department., Madrid, Spain
| | - Julio Galindo
- Hospital Universitario Ramón y Cajal, General Surgery Department., Madrid, Spain
| | - Eva Gonzalez Lizarbe
- Hospital Universitario Ramón y Cajal, Radiation Oncology Department., Madrid, Spain
| | - Constantino Varona
- Hospital Universitario Ramón y Cajal, Pathology Department., Madrid, Spain
| | - Jose Montans
- Pathology Department, Ramón y Cajal University Hospital, Madrid, Spain
| | - Julie Earl
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Enrique Grande
- Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain
| | | | - Pilar Garrido
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Eduardo Lobo
- Hospital Universitario Ramón y Cajal, General Surgery Department., Madrid, Spain
| | - José Palacios
- Hospital Universitario Ramon y Cajal, Pathology Department, Madrid, Spain
| | - Alfredo Carrato
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| |
Collapse
|
22
|
Guillen C, Earl J, Mocci E, Guerrero C, Montans J, Marquez M, Vazquez Sequeiros E, Gonzalez Gordaliza C, Sanjuanbenito A, MuÑoz MJ, Solera J, Real FX, Malats N, Carrato A. Genetic and phenotypic characterization of families with familial pancreatic cancer and screening of high-risk individuals. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.3_suppl.242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
242 Background: The prognosis of patients diagnosed with Pancreatic Cancer (PC) is dismal with a 5-year survival rate of around 5%. Familial Pancreatic Cancer (FPC) is an autosomal dominant rare syndrome defined as families with two or more first-degree relatives with pancreatic cancer that do not fulfill the criteria of any other inherited tumor syndrome. The Spanish familial pancreatic cancer registry, Pan-Gen-FAM was established in 2009 in order to identify and manage families at high risk of developing PC. Methods: Information on the family history of cancer is collected in order to determine the phenotype of individual families and patients are offered genetic testing of known FPC associated genes pertinent to their familial syndrome. An individualized clinical screening program is devised for the early detection of a pancreatic tumor consisting of periodic monitoring by imaging techniques (EUS and MRI) and the evaluation of minimally-invasive tumor biomarkers approaches including Circulating Tumor Cells (CTC) and circulating free DNA in blood. Results: To date the registry includes 125 individuals representing some 41 families. Of 17 families tested so far BRCA2 germline mutations were detected in 5 families and a BRCA1 mutation in 1 family. 43 individuals underwent clinical screening. More pancreatic abnormalities were found by EUS (41%) than by MRI (31%). The most frequent abnormal findings were parenchymal changes associated with chronic pancreatitis. Eight cystic lesions were identified. One lesion was identified as a well differentiated neuroendocrine tumor and another was shown to have benign cytology and whilst carcinoma was found in a third patient, this patient underwent a subsequent partial pancreatectomy. The remaining patients with cystic lesions are undergoing close clinical observation. Seventy three patients underwent CTC determinations and all patients tested negative. Conclusions: Periodic screening of high risk individuals by EUS and RMI can detect small tumors and premalignant lesions. We hypothesize that these persons will have a higher probability of long-term survival than sporadic cases.
Collapse
Affiliation(s)
- Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Julie Earl
- Medical Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - Evelina Mocci
- Familial Cancer Unit, Medical Oncology Department, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain
| | - Carme Guerrero
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Jose Montans
- Pathology Department, Ramón y Cajal University Hospital, Madrid, Spain
| | | | | | | | - Alfonso Sanjuanbenito
- General and Digestive Surgery Department, Ramón y Cajal University Hospital, Madrid, Spain
| | | | - Jesus Solera
- Instituto Genetica Molecular, Hospital La Paz, Madrid, Spain
| | | | - Nuria Malats
- Spanish National Cancer Research Centre, Madrid, Spain
| | - Alfredo Carrato
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| |
Collapse
|
23
|
Stockfleth E, Peris K, Guillen C, Cerio R, Basset‐Seguin N, Foley P, Sanches J, Culshaw A, Erntoft S, Lebwohl M. Physician perceptions and experience of current treatment in actinic keratosis. J Eur Acad Dermatol Venereol 2014; 29:298-306. [DOI: 10.1111/jdv.12530] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Accepted: 03/21/2014] [Indexed: 11/30/2022]
Affiliation(s)
| | - K. Peris
- Department of Dermatology Catholic University of Rome, Italy
| | - C. Guillen
- Instituto Valenciano de Oncologia Valencia Spain
| | - R. Cerio
- Skin Centre Barts and The London NHS Trust London UK
| | | | - P. Foley
- Department of Medicine (Dermatology) The University of Melbourne St Vincent's Hospital Melbourne and Skin & Cancer Foundation Inc Carlton Australia
| | - J. Sanches
- Universidade de Sao Paulo Sao Paulo Brazil
| | | | | | | |
Collapse
|
24
|
Longo F, Grande E, Guillen C, Pachon V, Rodriguez Garrote M, Ferreiro R, Vaz MA, Alcalde R, Gomez A, Roberts E, Cortez P, Cortes A, Munoz J, Garcia De Paredes M, Guerrero C, Earl J, Olmedo Garcia ME, Garrido P, Palacios J, Carrato A. Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e15019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Federico Longo
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Enrique Grande
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Vanessa Pachon
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | | | - Reyes Ferreiro
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Maria Angeles Vaz
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Rebeca Alcalde
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Ana Gomez
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Eduardo Roberts
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Patricia Cortez
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Alfonso Cortes
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Jacobo Munoz
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | | | - Carme Guerrero
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Julie Earl
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | | | - Pilar Garrido
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - José Palacios
- Hospital Universitario Ramon y Cajal, Pathology Department, Madrid, Spain
| | - Alfredo Carrato
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| |
Collapse
|
25
|
Abad A, Massuti B, Gravalos C, Escudero P, Guillen C, Manzano JL, Gomez M, Safont MJ, Gallego Plazas J, Sastre J, Pericay C, Dueñas R, López-López C, Losa F, Valladares Ayerbes M, González E, Yuste A, Carrato A, Aranda E. Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.3560] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Albert Abad
- University Hospital Germans Trias i Pujol-ICO, Barcelona, Spain
| | | | | | - Pilar Escudero
- Hospital Clínico, Universitario Lozano Blesa, Zaragoza, Spain
| | - Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Jose Luis Manzano
- Institut Català d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain
| | - M.Auxiliadora Gomez
- Medical Oncology Department, University Reina Sofia Hospital, Biomedical Research Institute Maimonidas, Cordoba, Spain
| | | | | | - Javier Sastre
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Carles Pericay
- Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Spain
| | | | | | | | | | | | - Ana Yuste
- Hospital General Universitario, Alicante, Spain
| | - Alfredo Carrato
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | | |
Collapse
|
26
|
Benavides M, Gallego Plazas J, Guillen C, Vera R, Iranzo V, Diaz IALES, Arevalo S, Pisa A, Martin-Richard M, Salud Salvia A, Falco E, Saenz A, Manzano JL, Pulido G, Martínez-Galán J, Pazo Cid RA, Rivera F, Garcia T, Irigoyen A, Aranda E. Gemcitabine(G)/erlotinib(E) versus gemcitabine/erlotinib/capecitabine(C) in the first-line treatment of patients with metastatic pancreatic cancer (mPC): Efficacy and safety results of a phase IIb randomized study from the Spanish TTD Collaborative Group. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.4122] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Carmen Guillen
- Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain
| | - Ruth Vera
- Service of Medical Oncology, Hospital de Navarra, Pamplona, Spain
| | - Vega Iranzo
- Hospital General Universitario de Valencia, Valencia, Spain
| | | | | | - Aleydis Pisa
- Institut Oncològic del Vallès, Corporació Sanitària Parc Taulí - Consorci Sanitari de Terrassa, Sabadell, Spain
| | | | | | | | | | - Jose Luis Manzano
- Institut Català d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain
| | - Gema Pulido
- Medical Oncology Department University Reina Sofía Hospital, Cordoba, Spain
| | | | - Roberto A. Pazo Cid
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
| | - Fernando Rivera
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Teresa Garcia
- Hematology and Medical Oncology Department, University Hospital Morales Meseguer, UMU, IMIB, Murcia, Spain
| | - Antonio Irigoyen
- Medical Oncology Department. Hospital Virgen de la Salud, Toledo, Spain
| | | |
Collapse
|
27
|
|
28
|
Jimenez-Marco T, Fisa R, Riera C, Girona-Llobera E, Sedeño M, Saura A, Iniesta L, Guillen C, Muncunill J. Pathogen inactivation technology applied to a blood component collected from an asymptomatic carrier ofLeishmania infantum: a case report. Vox Sang 2012; 103:356-8. [DOI: 10.1111/j.1423-0410.2012.01622.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Isla D, Provencio M, Majem M, Felip E, Vinolas N, Campelo RG, de las Penas R, Carcereny E, Alberola V, Domine M, Blanco R, Dorta J, Bernabé R, Guillen C, Vadell C, Maestu I, Rodriguez D, Rubio-Viqueira B, Figueroa S, Garrido López P. Never-smoking women with lung cancer from the Spanish WORLD07 database. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1531] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1531 Background: Gender differences in lung cancer (LC) have been reported, but with many unresolved issues yet. Tobacco causes the majority of women lung cancer (WLC), although the rate of never-smoking WLC is higher than in men. Several factors may play etiologic roles, and an in-depth understanding is needed. Methods: WORLD07 is a Spanish prospective, multicenter, epidemiologic female-specific LC database sponsored by ICAPEM, a professional association committed with WLC research. In order to improve the knowledge on never-smoking WLC, information has been extracted from WORLD07 database. Results: From October/2007 to October/2011, 1371 newly diagnosed WLC were included in an e-database from 32 centers, 539 (39.3%) never-smoking. Patient (p) characteristics: median age 71.1 years(y); median age of menarche 13y.; motherhood 91.2% (median 2.3 children, median age at first child 26.4y); oral contraceptive use 11.9%; postmenopausal 88.9% (median age of menopause 49y); HRT 5.2%; second-hand smokers 40% (work-exposure 17.1%, home-exposure 88.8%); obesity 16.3%; familiar history of cancer 39.9% (LC 29.8%); previous history of cancer 13% (breast/lung/cervix: 41.4/5.7/2.9%); current LC histology(%): adenocarcinoma/SqCC/LCC/SCLC: 83.4/6.2/5.5/3.9; EGFR mut+ (268 p analyzed): 55.5% (exon 19/20/21(%): 61.1/7.4/36.9); TNM NSCLC I/II/III/IV(%): 14/3.3/19.8/60.3. Treatment: EGFR-TKI in p EGFR mut+, stage IV(1st-/2nd-line)(%): 51.7/15.4; stage IV NSCLC (1st-line/2nd-line): platinum-based CT 42.5%, EGFR-TKI 33.5%, combinations with bevacizumab 2.9% / EGFR-TKI 15.8%. Overall survival: median 27 months(m), 1/2-y(%) 74.8/55.2; stage IV NSCLC: median 20.5m, 1/2-y(%) 67/46; EGFR-mut+ p: median 27.3m, 1/2-y(%) 75/54.3. Conclusions: According to our e-database, WLC showed high rates of never-smokers (39.3%), and of relatives diagnosed with malignant tumours (39.9%, ≅1/3 LC). Adenocarcinoma was the most frequent histology (76.1%), and more than half of the cases analyzed harboured EGFR mutations. Although 40% were second-hand smokers, further investigations are warranted. Survival outcomes remain satisfactory, as expected from this selected subgroup of p. Additional epidemiologic and treatment data will be presented.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Enric Carcereny
- Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain
| | | | - Manuel Domine
- Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain
| | | | - Javier Dorta
- Hospital Univ. Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain
| | | | | | | | | | - Delvys Rodriguez
- Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | | | | | | | | |
Collapse
|
30
|
Jimenez J, Perez C, Guillen C, Tejerizo A, Lopez G, Cruz C. Laparoscopic Surgical Ganglionar Debulking in a Platinum-Taxol Refractory Ovarian Cancer Patient. J Minim Invasive Gynecol 2011. [DOI: 10.1016/j.jmig.2011.08.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
van der Leest RJT, de Vries E, Bulliard JL, Paoli J, Peris K, Stratigos AJ, Trakatelli M, Maselis TJEML, Situm M, Pallouras AC, Hercogova J, Zafirovik Z, Reusch M, Olah J, Bylaite M, Dittmar HC, Scerri L, Correia O, Medenica L, Bartenjev I, Guillen C, Cozzio A, Bogomolets OV, del Marmol V. The Euromelanoma skin cancer prevention campaign in Europe: characteristics and results of 2009 and 2010. J Eur Acad Dermatol Venereol 2011; 25:1455-65. [PMID: 21951235 DOI: 10.1111/j.1468-3083.2011.04228.x] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Euromelanoma is a skin cancer education and prevention campaign that started in 1999 in Belgium as 'Melanoma day'. Since 2000, it is active in a large and growing number of European countries under the name Euromelanoma. OBJECTIVE To evaluate results of Euromelanoma in 2009 and 2010 in 20 countries, describing characteristics of screenees, rates of clinically suspicious lesions for skin cancer and detection rates of melanomas. METHODS Euromelanoma questionnaires were used by 20 countries providing their data in a standardized database (Belgium, Croatia, Cyprus, Czech Republic, FYRO Macedonia, Germany, Greece, Hungary, Italy, Lithuania, Luxembourg, Malta, Moldavia, Portugal, Serbia, Slovenia, Spain, Sweden, Switzerland and Ukraine). RESULTS In total, 59,858 subjects were screened in 20 countries. Most screenees were female (64%), median ages were 43 (female) and 46 (male) and 33% had phototype I or II. The suspicion rates ranged from 1.1% to 19.4% for melanoma (average 2.8%), from 0.0% to 10.7% for basal cell carcinoma (average 3.1%) and from 0.0% to 1.8% for squamous cell carcinoma (average 0.4%). The overall positive predictive value of countries where (estimation of) positive predictive value could be determined was 13.0%, melanoma detection rates varied from 0.1% to 1.9%. Dermoscopy was used in 78% of examinations with clinically suspected melanoma; full body skin examination was performed in 72% of the screenees. CONCLUSION Although the population screened during Euromelanoma was relatively young, high rates of clinically suspected melanoma were found. The efficacy of Euromelanoma could be improved by targeting high-risk populations and by better use of dermoscopy and full body skin examination.
Collapse
Affiliation(s)
- R J T van der Leest
- Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Messeguer F, Serra-Guillen C, Echeverria B, Requena C, Sanmartin O, Llombart B, Guillen C, Nagore E. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod. J Eur Acad Dermatol Venereol 2011; 26:879-81. [DOI: 10.1111/j.1468-3083.2011.04177.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
33
|
Serra-Guillen C, Nagore E, Hueso L, Llombart B, Requena C, Sanmartín O, Botella-Estrada R, Guillen C. A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. Br J Dermatol 2011; 164:429-33. [PMID: 20973770 DOI: 10.1111/j.1365-2133.2010.10098.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Photodynamic therapy (PDT) and imiquimod are two excellent treatments for actinic keratosis but are often not well tolerated by patients. OBJECTIVES To ascertain which treatment is better tolerated and which produces greater patient satisfaction. A secondary objective was to determine the factors related to the patient's tolerance to each treatment. METHODS Patients with at least five actinic keratosis lesions on the face and scalp were selected. The patients were randomized to receive treatment with PDT with methyl aminolaevulinate or treatment with imiquimod. Tolerance, satisfaction and predisposition to repeat the treatment were evaluated. RESULTS Most patients exhibited good or acceptable tolerance to both PDT and imiquimod treatment. There was a higher percentage of patients treated with PDT (93%) who were very satisfied compared with imiquimod (62%) (P=0·004). Most patients treated with either one of the two options would repeat the same treatment. No significant relationship was found between age, sex, working time exposed to the sun, phototype and hair colour and the tolerance to both treatments. CONCLUSIONS Both PDT and imiquimod are treatments that are generally well tolerated. While both treatments provide a high level of satisfaction, PDT appears to be slightly superior in this regard.
Collapse
Affiliation(s)
- C Serra-Guillen
- Department of Dermatology, Instituto Valenciano de Oncología, c/Profesor Beltran Baguena 8, Valencia 46009, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
Mast cell-derived prostaglandin D2 (PGD2) is the major prostanoid found within the airway of asthmatics immediately following allergen challenge. PGD2 has been shown to have chemokinetic effects on eosinophils and T helper type 2 (Th2) cells in vitro. This occurs through the interaction of PGD2 with the G-protein-coupled chemokine receptor homologous molecule expressed on Th2 lymphocytes (CRTH2). The expression of CRTH2 has been shown to be highly selective for Th2 cells. Using flow cytometry we have studied the expression of CRTH2 on T cells in blood and bronchoalveolar lavage fluid in asthmatics and normal subjects. CRTH2 expression was confined to a small percentage of blood T cells in asthmatics (1.8%+/-0.2) and normal (1.6%+/-0.2) subjects. CRTH2 was enriched significantly on interleukin (IL)-4+/IL-13+ T cells compared to interferon (IFN)-gamma+ T cells (P<0.001). There was a small population of CRTH2+ T cells in the bronchoalveolar lavage (BAL) of asthmatics (2.3%+/-0.6) and normal subjects (0.3%+/-0.1), and there was a significant difference between the two groups (P<0.05). There were similar amounts of PGD2 in the BAL of asthma and normal subjects. Within paired blood-BAL samples from the same subject there was no increase in CRTH2+ T cells in the BAL compared to blood in asthmatics. Enrichment of CRTH2 on IL-4+ and IL-13+ T cells compared to IFN-gamma+ T cells was also seen in BAL from asthmatics (P<0.001). CRTH2 is expressed preferentially by IL-4+/IL-13+ T cells compared to IFN-gamma+ T cells. However, given their small numbers they are unlikely to have a significant involvement in the pathogenesis of asthma. CRTH2 antagonism may not diminish T cell accumulation in the asthmatic lung.
Collapse
Affiliation(s)
- K Mutalithas
- Institute for Lung Health, Department of Infection Immunity and Inflammation, University Hospitals of Leicester, Leicester, UK
| | | | | | | | | | | |
Collapse
|
35
|
Abstract
Background Chemokines and their receptors could play key roles in the recruitment of T cells to the asthmatic lung. CCR8 is preferentially expressed on T-helper type 2 cells, and is thought to play a role in the pathogenesis of human asthma. Objective Determine the expression of CCR8 on T cells in blood, bronchoalveolar lavage (BAL) and bronchial mucosa from asthmatics and normal subjects. Methods CCR8 expression in blood and BAL from asthma and normal subjects was studied using flow cytometry. CCR8 expression on IFN-γ+ and IL-4+/IL-13+ blood and BAL T cells was studied following stimulation with Phorbol–Myristate–Acetate and Calcium Ionophore. Paraffin-embedded bronchial biopsies were used to study CCR8 in bronchial epithelium. Results The percentage of CD3+ cells expressing CCR8 in the blood was higher in asthmatics (4.7±0.4%) compared with normal subjects (3.0±0.4%; P<0.01). There was an approximately sixfold enrichment of CCR8 on IL-4+/IL-13+ cells compared with IFN-γ+ T cells (P<0.001) in both asthmatic and normal subjects in both blood and BAL. Significantly more BAL T cells expressed CCR8 in asthmatic (8.6±0.8%) compared with normal subjects (3.9±0.7%) (P<0.01). In paired blood-BAL samples from asthmatics, significantly more CCR8+CD3+ T cells were present in BAL (9.0±0.9%) than in blood (5.6±0.9%; P<0.05). There were more CCR8-positive cells in bronchial biopsies from asthmatic (93±11 cells/mm2) compared with normal subjects (30±16 cells/mm2) (P<0.05). The ligand CCL1 was increased in the BAL of asthmatics compared with normal subjects (35±6 vs. 12.9±7 pg/mL; P<0.05). Conclusion There may be a role for CCR8 in the recruitment of T cells to the lung in asthmatics. Cite this as: K. Mutalithas, C. Guillen, C. Raport, R. Kolbeck, D. Soler, C. E. Brightling, I. D. Pavord and A. J. Wardlaw, Clinical & Experimental Allergy, 2010 (40) 1175–1185.
Collapse
Affiliation(s)
- K Mutalithas
- Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, UK
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Nagore E, Hueso L, Botella-Estrada R, Alfaro-Rubio A, Serna I, Guallar JP, González I, Ribes I, Guillen C. Smoking, sun exposure, number of nevi and previous neoplasias are risk factors for melanoma in older patients (60 years and over). J Eur Acad Dermatol Venereol 2010; 24:50-7. [DOI: 10.1111/j.1468-3083.2009.03353.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
37
|
Jimenez J, Marqueta L, Alvarez C, Muñoz L, Gonzalez Macho C, Guillen C, Bravo V. Dermatomiosytis: Paraneoplastic Syndrome in a Postmenopausal Woman. J Minim Invasive Gynecol 2009. [DOI: 10.1016/j.jmig.2009.08.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
38
|
Marqueta L, Muñoz L, Jimenez J, Lorenzo E, Seoane J, Guillen C, Gonzalez Macho C, Lopez G. Diagnostic Accuracy by the Presence of Symptoms: Ambulatory Hysteroscopy in Postmenopausal Women. J Minim Invasive Gynecol 2009. [DOI: 10.1016/j.jmig.2009.08.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Lorenzo E, Jimenez J, Gonzalez Macho C, Guillen C, Lopez G, Tejerizo A. Presurgical Valuation. Endocervical Affectation in Stage II of the Endometrial Cancer. J Minim Invasive Gynecol 2009. [DOI: 10.1016/j.jmig.2009.08.346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
40
|
Majem M, Domine M, Lianes P, Dorta F, Catot S, Guillen C, De las Peñas R, Vadell C, Amador M, Rosell R. 9031 Lung cancer in women: the Spanish female-specific database WORLD 07. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71744-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
41
|
Serra-Guillen C, Hueso L, Nagore E, Vila M, Llombart B, Requena Caballero C, Botella-Estrada R, Sanmartin O, Alfaro-Rubio A, Guillen C. Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol 2009; 161:353-6. [DOI: 10.1111/j.1365-2133.2009.09184.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
42
|
Valenzuela I, Balmaña J, Rue M, Blanco I, Torres A, Ramon y Cajal T, Chirivella I, Guillen C, Brunet J, Tejada I. Comparison of Lynch predictive models for identification of MLH1/MSH2 mutation carriers in a Spanish multicentre clinic- based cohort. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22077 Background: Different predictive models for Lynch syndrome have recently been developed and their comparative performance in a clinic-based cohort has not been assessed. We aimed to analyze the accuracy of the MMRpro, Barnetson, and PREMM1,2 models to predict MLH1/MSH2 mutation carrier status in 564 unrelated probands with clinical suspicion of hereditary colorectal cancer and compare it with Wijnen model and clinical criteria. Methods: Overall, 538 individuals (95%) underwent mismatch repair (MMR) deficiency screening before germline genetic testing (sequencing with or without large rearrangement analysis) and 26 (5%) performed direct genetic testing. Prediction scores for all individuals were calculated by each model. Sensitivity, specificity, positive predictive value (PPV), and the areas under the receiver operating characteristics curves (AUC) for all models were calculated and compared with the Revised Bethesda Guidelines (RBG). Results: 114 individuals (20%) were mutation carriers (63 MLH1, 51 MSH2). The AUC was 0.95 (95% CI: 0.93–0.97) for MMRpro, 0.87 (95% CI 0.83–0.91) for the Barnetson model, 0.87 (95% CI 0.83–0.91) for PREMM1,2, and 0.75 (95% CI 0.69–0.80) for the Wijnen model (p<0.001). Testing thresholds and specificity at 100% and 90% sensitivity for each model were: 0.001/17% and 0.33/89% for MMRpro, 0.01/9% and 0.07/59% for Barnetson, 0.05/5% and 0.11/58% for PREMM1,2. Sensitivity and specificity of RBG were 86% and 14%, respectively. Calibration was 0.92, 1.05, 0.50, and 1.25 for PREMM1,2,Barnetson, Wijnen, and MMRpro, respectively. Conclusions: In a population of individuals at risk of Lynch syndrome, the MMRpro model has the largest AUC, although the Barnetson and PREMM1,2 model also show adequate discrimination. Any of the models perform better than the RBG and provide quantitative risk estimation of finding a MLH1/MSH2 mutation useful in genetic counselling. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- I. Valenzuela
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - J. Balmaña
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - M. Rue
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - I. Blanco
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - A. Torres
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - T. Ramon y Cajal
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - I. Chirivella
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - C. Guillen
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - J. Brunet
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| | - I. Tejada
- Hospital Vall Hebron, Barcelona, Spain; School of Medicine, Lleida University, Lleida, Spain; ICO-Hospital Duran y Reynals, Barcelona, Spain; Hospital Sant Joan de Reus, Reus, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital Clinico Universitario, Valencia, Spain; Hospital General Universitario, Elche, Spain; ICO-Hospital Josep Trueta, Girona, Spain; Hospital Cruces, Bilbao, Spain; Hereditary Cancer Group of the Spanish Medical Oncology Society
| |
Collapse
|
43
|
Guillen C, Muñoz L, Marqueta L, Perez C, Tejerizo A, Muñoz J, Jimenez J, Hernandez J. AMBULATORY HYSTEROSCOPY IN POSTMENOPAUSAL WOMEN. DIAGNOSTIC ACCURACY BY THE PRESENCE OF SYMPTOMS. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70438-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Jimenez J, Guillen C, Sagaseta CP, Bravo V, Alvarez C, Gonzalez C, Hernandez Ga J. ENDOCERVICAL AFFECTATION IN STAGE II OF THE ENDOMETRIAL CANCER. PRESURGICAL VALUATION. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70479-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
45
|
Day CE, Zhang SD, Riley J, Gant T, Wardlaw AJ, Guillen C. A novel method for isolation of human lung T cells from lung resection tissue reveals increased expression of GAPDH and CXCR6. J Immunol Methods 2009; 342:91-7. [PMID: 19133266 PMCID: PMC2666793 DOI: 10.1016/j.jim.2008.12.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2008] [Revised: 12/01/2008] [Accepted: 12/03/2008] [Indexed: 11/20/2022]
Abstract
Lung T lymphocytes are important in pulmonary immunity and inflammation. It has been difficult to study these cells due to contamination with other cell types, mainly alveolar macrophages. We have developed a novel method for isolating lung T cells from lung resection tissue, using a combination of approaches. Firstly the lung tissue was finely chopped and filtered through a nylon mesh. Lymphocytic cells were enriched by Percoll density centrifugation and the T cells purified using human CD3 microbeads, resulting in 90.5%+/-1.9% (n=11) pure lymphocytes. The T cell yield from the crude cell preparation was 10.8+/-2.1% and viability, calculated using propidium iodide (PI) staining and trypan blue, was typically over 95%. The purification process did not affect expression of CD69 or CD103, nor was there a difference in the proportion of CD4 and CD8 cells between the starting population and the purified cells. Microarray analysis and real time RT-PCR revealed upregulation of GAPDH and CXCR6 of the lung T cells as compared to blood-derived T cells. This technique highly enriches lung T cells to allow detailed investigation of the biology of these cells.
Collapse
Affiliation(s)
- C E Day
- Institute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Glenfield Hospital, Leicester, United Kingdom.
| | | | | | | | | | | |
Collapse
|
46
|
Montenegro PC, Carrato A, Castillejo A, Balaguer TM, Barbera VM, Ochoa E, Andrada E, Guillen C, Casanova L, Soto J. Lack of an association between human papillomavirus (HPV) infection and colorectal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
47
|
Nagore E, Botella-Estrada R, Garcia-Casado Z, Requena C, Serra-Guillen C, Llombart B, Sanmartin O, Guillen C. Comparison between familial and sporadic cutaneous melanoma in Valencia, Spain. J Eur Acad Dermatol Venereol 2008; 22:931-6. [PMID: 18355200 DOI: 10.1111/j.1468-3083.2008.02682.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Some clinical, pathological and genetic features have been associated to familial melanoma, particularly multiple melanoma and earlier age at diagnosis. To compare the clinical, epidemiological and pathological differences between familial and sporadic melanoma patients in Valencia, Spain, a series of 959 patients with cutaneous melanoma were selected at a single institution. For this study the following variables were selected: age, sex, melanoma site and presence of solar lentigines on the melanoma surrounding skin, histological subtype, tumor thickness, stage, family and personal history of cutaneous melanoma and of other neoplasias, personal history of non-melanoma skin cancer, past personal history of severe sunburns, cutaneous phenotype (phototype, hair and eyes colors number of common nevus, number of atypical nevi, presence of solar lentigines). Forty-one (4.28%) familial and 918 sporadic melanoma were identified. Among the multiple variables studied, a younger age at diagnosis (median age of 42 vs 53 years), higher frequency of the presence of at least one clinically atypical nevus (36.1% vs 17.7%), multiple melanomas (12.2% vs 3.4%) and red/blonde hair (33.3% vs 18.9%), and a lower rate of cases with solar lentigines in melanoma site (33.3% vs 56.3%) were found for familial cases. Except for hair color and age, the other variables remained statistically significant after the multivariate study. Interestingly, no acral melanomas were found among the familial cases. In summary, phenotypic risk factors for familial melanoma are a tendency to develop multiple melanomas, to have clinically atypical nevi and to present less actinic damage at the melanoma site. All these results enhance the relevancy of genetic susceptibility associated to the ability to produce atypical nevi and partly to a higher sensitivity to the sun.
Collapse
Affiliation(s)
- E Nagore
- Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Lorenzo E, Jimenez Lopez J, Guillen C, Noguero R, Muñoz J. 186: Role of Hysteroscopic Biopsy in the Screening of Endometrial Pathology in Tamoxifen Treated Breast Cancer Patients. J Minim Invasive Gynecol 2007. [DOI: 10.1016/j.jmig.2007.08.151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Garcia L, Nagore E, Llombart B, Sanmartin O, Botella-Estrada R, Requena C, Jorda E, Guillen C. Basal cell carcinoma of the nasolabial fold: an apparently ‘benign’ tumour that often needs complex surgery. J Eur Acad Dermatol Venereol 2006; 20:926-30. [PMID: 16922939 DOI: 10.1111/j.1468-3083.2006.01673.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Location of the tumour is a well-known prognostic factor for recurrence of basal cell carcinoma (BCC). We have observed that tumours located in the nasolabial fold may deserve a particular attention. OBJECTIVE The aim of this study is to evaluate the behaviour of BCC located on the nasolabial fold in comparison to a control group of patients with BCC in lower risk sites, and to detect characteristics which may imply a more complicated treatment or the consideration of adjuvant treatment. METHODS A series of 24 patients with BCC located on the nasolabial fold were retrospectively recruited from our database of Mohs surgery from January 1997 to December 2000. A control group of 37 patients with BCC located on the cheek or forehead were selected from the same database. The differences between both groups in clinical, surgical and histological terms were evaluated. RESULTS BCC on the nasolabial fold presented with shorter evolution time from first symptom, had a smaller size, had been less frequently treated before and showed mostly non-aggressive histologic subtype, but needed more surgical stages and more complex reconstruction. CONCLUSION We have observed that BCC on the nasolabial fold, despite presenting with better clinical and histological features, needed more complicated surgery. In our opinion, this location warrants a particular attention and further prospective studies should be made to corroborate our findings.
Collapse
Affiliation(s)
- L Garcia
- Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Morgan AJ, Guillen C, Symon FA, Huynh TT, Berry MA, Entwisle JJ, Briskin M, Pavord ID, Wardlaw AJ. Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy 2006; 35:1572-80. [PMID: 16393323 DOI: 10.1111/j.1365-2222.2005.02383.x] [Citation(s) in RCA: 71] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Chemokine receptors (CR) play an important role in T cell migration, but their contribution to lung trafficking is unclear. OBJECTIVE We hypothesized that if a particular CR was involved in T cell homing its expression would be enriched on lung T cells compared with peripheral blood T cells (PBT). METHODS We have measured the CR expression on BAL T cells from patients with sarcoid, other interstitial lung diseases (ILD), asthma and healthy volunteers. RESULTS Of 14 CR studied in sarcoid, CXCR6 expression was the most markedly increased in the lung compared with the blood, a finding that was also seen in ILD patients. A striking although lesser increase was also seen in asthmatics and healthy controls. Analysis of expression of the CXCR6 ligand, CXCL16, by immunohistochemistry suggested that alveolar macrophages (AM) were the major source of CXCL16 in the lung. AM expressed mRNA for CXCL16 and released nanogram quantities after adhesion to plastic as shown by RT-PCR, Western blotting and ELISA. Bronchoalveolar lavage (BAL) fluid from all subjects contained large amounts of CXCL16. The full-length CXCL16 was the predominant isoform in AM lysates, supernatants and BAL. CONCLUSION This data suggests that CXCR6 and CXCL16 may play a role in T cell recruitment to the lung.
Collapse
MESH Headings
- Adult
- Asthma/immunology
- Biomarkers/analysis
- Blotting, Western
- Bronchoalveolar Lavage Fluid/chemistry
- Case-Control Studies
- Chemokine CXCL16
- Chemokines, CXC/analysis
- Chemokines, CXC/blood
- Chemokines, CXC/genetics
- Female
- Flow Cytometry
- Humans
- Immunohistochemistry/methods
- Lung/immunology
- Lung Diseases/immunology
- Lymphocyte Count
- Macrophages, Alveolar/immunology
- Male
- Pulmonary Fibrosis/immunology
- RNA, Messenger/analysis
- Receptors, CXCR6
- Receptors, Chemokine
- Receptors, Cytokine/analysis
- Receptors, Cytokine/blood
- Receptors, Cytokine/genetics
- Receptors, G-Protein-Coupled/analysis
- Receptors, G-Protein-Coupled/blood
- Receptors, G-Protein-Coupled/genetics
- Receptors, Scavenger/analysis
- Receptors, Scavenger/blood
- Receptors, Scavenger/genetics
- Receptors, Virus/analysis
- Receptors, Virus/blood
- Receptors, Virus/genetics
- Sarcoidosis/immunology
- T-Lymphocytes/chemistry
Collapse
Affiliation(s)
- A J Morgan
- Institute for Lung Health, Department of Infection, Immunity and Inflammation, Leicester University, Glenfield Hospital, Leicester, UK
| | | | | | | | | | | | | | | | | |
Collapse
|